Fig. 3

Verification and further characterization of selected compounds. a Neuroprotective properties of selected compounds were verified in independent NMDA toxicity assays using the same method as for the initial screen. The raw data on the upper axes depicts cell viability in NMDA-treated cells (shared among all comparisons) versus cells that were treated with NMDA plus the indicated compounds. A comparison between NMDA-treated and untreated cells is shown as a reference on the right. Each paired set of observations is connected by a line and represents the mean of an individual experiment. On the lower axes, each paired mean difference is plotted as a bootstrap sampling distribution. Mean differences are depicted as dots; 95% confidence intervals are indicated by the vertical error bars. The p values of the two-sided permutation t-tests are: NMDA vs NMDA + E, 0.000; NMDA vs NMDA + D, 0.000; NMDA vs NMDA + O, 0.000; NMDA vs NMDA + F, 0.067; NMDA vs NMDA + I, 0.448; NMDA vs untreated, 0.000. For each permutation p value, 5000 reshuffles of the control and test labels were performed. b Neurons were treated with 30 μM NMDA for 10 min and the indicated compounds were added 30 or 120 min after washout of NMDA. Protection scores were determined after 20 h. Round symbols represent the mean of each independent experiment, horizontal lines represent the mean of all experiments, error bars indicate the SD. c Neurons were treated for 48 h with 0.1% DMSO, 1 μM Elvitegravir, or 10 μM Elvitegravir and results were normalized to values from DMSO-treated controls. Round symbols represent the mean of each independent experiment, horizontal lines represent the mean of all experiments, error bars indicate the SD. Abbreviations are: untreated, no NMDA; D, Dutasteride; E, Elvitegravir; F, Finasteride; I, Isoniazid; O, Oxybutynin